122 related articles for article (PubMed ID: 15584481)
1. Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis.
Ehling R; Lutterotti A; Wanschitz J; Khalil M; Gneiss C; Deisenhammer F; Reindl M; Berger T
Mult Scler; 2004 Dec; 10(6):601-6. PubMed ID: 15584481
[TBL] [Abstract][Full Text] [Related]
2. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit.
Silber E; Semra YK; Gregson NA; Sharief MK
Neurology; 2002 May; 58(9):1372-81. PubMed ID: 12011283
[TBL] [Abstract][Full Text] [Related]
3. Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.
Amor S; van der Star BJ; Bosca I; Raffel J; Gnanapavan S; Watchorn J; Kuhle J; Giovannoni G; Baker D; Malaspina A; Puentes F
Mult Scler; 2014 Sep; 20(10):1355-62. PubMed ID: 24515731
[TBL] [Abstract][Full Text] [Related]
4. [Neurofilament protein light in multiple sclerosis].
Zhang Y; Li X; Qiao J
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2745-9. PubMed ID: 18167263
[TBL] [Abstract][Full Text] [Related]
5. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis.
Fialová L; Bartos A; Svarcová J; Zimova D; Kotoucova J; Malbohan I
J Neuroimmunol; 2013 Sep; 262(1-2):113-20. PubMed ID: 23870535
[TBL] [Abstract][Full Text] [Related]
6. Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis.
Bartos A; Fialová L; Soukupová J; Kukal J; Malbohan I; Pit'ha J
J Neurol; 2007 Jan; 254(1):20-5. PubMed ID: 17508137
[TBL] [Abstract][Full Text] [Related]
7. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis.
Romme Christensen J; Börnsen L; Khademi M; Olsson T; Jensen PE; Sørensen PS; Sellebjerg F
Mult Scler; 2013 Jun; 19(7):877-84. PubMed ID: 23178691
[TBL] [Abstract][Full Text] [Related]
8. Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy.
Eikelenboom MJ; Petzold A; Lazeron RH; Silber E; Sharief M; Thompson EJ; Barkhof F; Giovannoni G; Polman CH; Uitdehaag BM
Neurology; 2003 Jan; 60(2):219-23. PubMed ID: 12552034
[TBL] [Abstract][Full Text] [Related]
9. Antibodies against light neurofilaments in multiple sclerosis patients.
Bartos A; Fialová L; Soukupová J; Kukal J; Malbohan I; Pitha J
Acta Neurol Scand; 2007 Aug; 116(2):100-7. PubMed ID: 17661795
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
Axelsson M; Malmeström C; Gunnarsson M; Zetterberg H; Sundström P; Lycke J; Svenningsson A
Mult Scler; 2014 Jan; 20(1):43-50. PubMed ID: 23702432
[TBL] [Abstract][Full Text] [Related]
11. CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.
Romme Christensen J; Komori M; von Essen MR; Ratzer R; Börnsen L; Bielekova B; Sellebjerg F
Mult Scler; 2019 Jun; 25(7):937-946. PubMed ID: 29775134
[TBL] [Abstract][Full Text] [Related]
12. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD
Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053
[TBL] [Abstract][Full Text] [Related]
13. Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis.
Puentes F; Topping J; Kuhle J; van der Star BJ; Douiri A; Giovannoni G; Baker D; Amor S; Malaspina A
J Neurol Neurosurg Psychiatry; 2014 Mar; 85(3):274-8. PubMed ID: 24078718
[TBL] [Abstract][Full Text] [Related]
14. High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients.
Hecker M; Fitzner B; Wendt M; Lorenz P; Flechtner K; Steinbeck F; Schröder I; Thiesen HJ; Zettl UK
Mol Cell Proteomics; 2016 Apr; 15(4):1360-80. PubMed ID: 26831522
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid and serum antibodies against neurofilaments in patients with amyotrophic lateral sclerosis.
Fialová L; Svarcová J; Bartos A; Ridzon P; Malbohan I; Keller O; Rusina R
Eur J Neurol; 2010 Apr; 17(4):562-6. PubMed ID: 19968709
[TBL] [Abstract][Full Text] [Related]
16. Serum autoantibodies to neurofilament proteins in sporadic amyotrophic lateral sclerosis.
Couratier P; Yi FH; Preud'homme JL; Clavelou P; White A; Sindou P; Vallat JM; Jauberteau MO
J Neurol Sci; 1998 Feb; 154(2):137-45. PubMed ID: 9562303
[TBL] [Abstract][Full Text] [Related]
17. Serum and cerebrospinal fluid heavy neurofilaments and antibodies against them in early multiple sclerosis.
Fialová L; Bartos A; Švarcová J; Zimova D; Kotoucova J
J Neuroimmunol; 2013 Jun; 259(1-2):81-7. PubMed ID: 23632043
[TBL] [Abstract][Full Text] [Related]
18. Patients with Alzheimer disease have elevated intrathecal synthesis of antibodies against tau protein and heavy neurofilament.
Bartos A; Fialová L; Svarcová J; Ripova D
J Neuroimmunol; 2012 Nov; 252(1-2):100-5. PubMed ID: 22948089
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of neurofascin-155 antibodies in patients with multiple sclerosis.
Stich O; Perera S; Berger B; Jarius S; Wildemann B; Baumgartner A; Rauer S
J Neurol Sci; 2016 May; 364():29-32. PubMed ID: 27084211
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.
Fainardi E; Castellazzi M; Bellini T; Manfrinato MC; Baldi E; Casetta I; Paolino E; Granieri E; Dallocchio F
Mult Scler; 2006 Jun; 12(3):294-301. PubMed ID: 16764342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
